Milena Urbini

Dr. Milena Urbini

Biosciences Laboratory, Translational Oncology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2013 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
OGon behalf of GIST Study Group
on behalf of GIST Study Group
MPmaria pantaleo
maria pantaleo
Annalisa AstolfiAnnalisa Astolfi
Annalisa Astolfi
Milena UrbiniMilena Urbini
Milena Urbini
MNMargherita Nannini
Margherita Nannini
GBGuido Biasco
Guido Biasco

10 August 2015 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
Silvia StacchiottiSilvia Stacchiotti
Silvia Stacchiotti
MPmaria pantaleo
maria pantaleo
TNTiziana Negri
Tiziana Negri
Annalisa AstolfiAnnalisa Astolfi
Annalisa Astolfi
MTMarcella Tazzari
Marcella Tazzari
PCPaolo G. Casali
Paolo G. Casali
Purpose:To report on imatinib mesylate (IM) in patients with metastatic dermatofibrosarcoma protuberans (DFSP)/ fibrosarcomatous (FS)-DFSP and on the impact of the treatment on tumor biology Experimental Design:Ten consecutive patients treated with IM from 2007 to 2015 for a metastatic relapse from DFSP/FS-DFSP were identified. FISH analysis for COL1A1-PDGFb was performed. Two IM-treated and 4 naïve FS-DFSP were transcriptionally profiled by RNAseq on HiScanSQ platform. Differential gene expression was analyzed with edgeR (Bioconductor), followed by hierarchical clustering and Principal Component Analysis (PCA). Results:All cases featured fibrosarcomatous in the metastasis and retained the COL1A1-PDGFB. Best RECIST response was: 8 PR, 1 SD, 1 PD. Median PFS was 11 months. Five patients received surgery after IM and all relapsed. IM was restored in 4 patients with a new response. After IM, the most up-regulated genes included those encoding for immunoglobulins and those affecting functions and differentiation of endothelial cells. Pathway enrichment analysis revealed up-regulation in genes involved in antigen processing and presentation, NK mediated cytotoxicity, and drug and xenobiotics metabolism. Conversely, a significant down-regulation of kinase signaling pathways was detected. Conclusions:All metastatic cases were fibrosarcomatous. Most patients responded to IM but PFS was shorter than reported in published series which included both DFSP and FS/DFSP. All patients operated after IM had a relapse, suggesting that IM cannot eradicate metastatic cases and that the role of surgery is limited. Transcriptional profile of naïve and post-treatment samples pointed the contribution of immune infiltrates in sustaining the response to IM.

23 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MCMatteo Canale
Matteo Canale
KAKalliopi Andrikou
Kalliopi Andrikou
IPIlaria Priano
Ilaria Priano
PCPaola Cravero
Paola Cravero
LPLuigi Pasini
Luigi Pasini
Paola UliviPaola Ulivi
Paola Ulivi
Non-Small-Cell Lung Cancer (NSCLC) is the primary cause of cancer-related death worldwide. Oncogene-addicted patients usually benefit from targeted therapy, but primary and acquired resistance mechanisms inevitably occur. Tumor protein 53 (TP53) gene is the most frequently mutated gene in cancer, including NSCLC. TP53 mutations are able to induce carcinogenesis, tumor development and resistance to therapy, influencing patient prognosis and responsiveness to therapy. TP53 mutants present in different forms, suggesting that different gene alterations confer specific acquired protein functions. In recent years, many associations between different TP53 mutations and responses to Epidermal Growth Factor Receptor (EGFR) targeted therapy in NSCLC patients have been found. In this review, we discuss the current landscape concerning the role of TP53 mutants to guide primary and acquired resistance to Tyrosine-Kinase Inhibitors (TKIs) EGFR-directed, investigating the possible mechanisms of TP53 mutants within the cellular compartments. We also discuss the role of the TP53 mutations in predicting the response to targeted therapy with EGFR-TKIs, as a possible biomarker to guide patient stratification for treatment.

31 July 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Annalisa AstolfiAnnalisa Astolfi
Annalisa Astolfi
MNMargherita Nannini
Margherita Nannini
VIValentina Indio
Valentina Indio
ASAngela Schipani
Angela Schipani
Alessandro RizzoAlessandro Rizzo
Alessandro Rizzo
MPmaria pantaleo
maria pantaleo
Uterine Leiomyosarcoma (uLMS) is by far the most common type of uterine sarcoma, characterized by an aggressive clinical course, a heterogeneous genetic profile and a very scarce response to cytotoxic chemotherapy. The genetic make-up of uLMS is an area of active study that could provide essential cues for the development of new therapeutic approaches. A total of 216 patients with uLMS from cBioPortal and AACR-GENIE databases were included in the study. The vast majority of patients (81%) carried at least one mutation in either TP53, RB1, ATRX or PTEN. The most frequently mutated gene was TP53, with 61% of the patients harboring at least one mutation, followed by RB1 at 48%. PTEN alteration was more frequent in metastases than in primary lesions, consistent with a later acquisition during tumor progression. There was a significant trend for TP53 and RB1 mutations to occur together, while both TP53 and RB1 were mutually exclusive with respect to CDKN2A/B inactivation. Overall survival did not show significant correlation with the mutational status, even if RB1 mutation emerged as a favorable prognostic factor in the TP53-mutant subgroup. This comprehensive analysis shows that uLMS is driven almost exclusively by the inactivation of tumor suppressor genes and suggests that future therapeutic strategies should be directed at targeting the main genetic drivers of uLMS oncogenesis.

20 September 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MNMargherita Nannini
Margherita Nannini
Annalisa AstolfiAnnalisa Astolfi
Annalisa Astolfi
Milena UrbiniMilena Urbini
Milena Urbini
VIValentina Indio
Valentina Indio
DSDonatella Santini
Donatella Santini
MPmaria pantaleo
maria pantaleo
About 10-15% of adult gastrointestinal stromal tumors (GIST) and the vast majority of pediatric GIST do not harbour KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutations (J Clin Oncol 22:3813–3825, 2004; Hematol Oncol Clin North Am 23:15–34, 2009). The molecular biology of these GIST, originally defined as KIT/PDGFRA wild-type (WT), is complex due to the existence of different subgroups with distinct molecular hallmarks, including defects in the succinate dehydrogenase (SDH) complex and mutations of neurofibromatosis type 1 (NF1), BRAF, or KRAS genes (RAS-pathway or RAS-P). In this extremely heterogeneous landscape, the clinical profile and molecular abnormalities of the small subgroup of WT GIST suitably referred to as quadruple wild-type GIST (quadruple WT or KIT WT/PDGFRA WT/SDH WT/RAS-P WT) remains undefined. The aim of this study is to investigate the genomic profile of KIT WT/PDGFRA WT/SDH WT/RAS-P WT GIST, by using a massively parallel sequencing and microarray approach, and compare it with the genomic profile of other GIST subtypes. We performed a whole genome analysis using a massively parallel sequencing approach on a total of 16 GIST cases (2 KIT WT/PDGFRA WT/SDH WT and SDHB IHC+/SDHA IHC+, 2 KIT WT/PDGFRA WT/SDHA mut and SDHB IHC-/SDHA IHC- and 12 cases of KIT mut or PDGFRA mut GIST). To confirm and extend the results, whole-genome gene expression analysis by microarray was performed on 9 out 16 patients analyzed by RNAseq and an additional 20 GIST patients (1 KIT WT/PDGFRA WT SDHA mut GIST and 19 KIT mut or PDGFRA mut GIST). The most impressive data were validated by quantitave PCR and Western Blot analysis. We found that both cases of quadruple WT GIST had a genomic profile profoundly different from both either KIT/PDGFRA mutated or SDHA-mutated GIST. In particular, the quadruple WT GIST tumors are characterized by the overexpression of molecular markers (CALCRL and COL22A1) and of specific oncogenes including tyrosine and cyclin- dependent kinases (NTRK2 and CDK6) and one member of the ETS-transcription factor family (ERG). We report for the first time an integrated genomic picture of KIT WT/PDGFRA WT/SDH WT/RAS-P WT GIST, using massively parallel sequencing and gene expression analyses, and found that quadruple WT GIST have an expression signature that is distinct from SDH-mutant GIST as well as GIST harbouring mutations in KIT or PDGFRA. Our findings suggest that quadruple WT GIST represent another unique group within the family of gastrointestintal stromal tumors.

3 November 2015 in BMC Genomics
Verified
Journal Article
Open access
PDF file
Annalisa AstolfiAnnalisa Astolfi
Annalisa Astolfi
Milena UrbiniMilena Urbini
Milena Urbini
VIValentina Indio
Valentina Indio
MNMargherita Nannini
Margherita Nannini
CGChiara Giusy Genovese
Chiara Giusy Genovese
MPmaria pantaleo
maria pantaleo
Next generation sequencing (NGS) technology has been rapidly introduced into basic and translational research in oncology, but the reduced availability of fresh frozen (FF) tumor tissues and the poor quality of DNA extracted from formalin-fixed, paraffin-embedded (FFPE) has significantly impaired this process in the field of solid tumors. To evaluate if data generated from FFPE material can be reliably produced and potentially used in routine clinical settings, we performed whole exome sequencing (WES) from tumor samples of Gastrointestinal stromal tumors (GIST), either extracted FF or FFPE, and from matched normal DNA. We performed whole exome enrichment and sequencing at 100bp in paired end on four GIST samples, either from FFPE or fresh-frozen tissue, and from matched normal DNA. The integrity of DNA extracted from FFPE was evaluated by a modified RAPD PCR method, thus identifying high quality (HQ) and low quality (LQ) FFPE. DNA library production and exome capture was feasible for both classes of FFPE, despite the smaller yield and insert size of LQ-FFPE. WES produced data of equal quality from FF and FFPE, while only HQ-FFPE yielded an amount of data comparable to FF samples. Bioinformatic analysis showed that the percentage of variants called both in FF and FFPE samples was very high in HQ-FFPE, reaching 94-96 % of the total number of called variants. Classification of somatic variants by nucleotide substitution type showed that HQ-FFPE and FF had similar mutational profiles, while LQ-FFPE samples carried a much higher number of mutations than the FF counterpart, with a significant enrichment of C > T/G > A substitutions. Focusing on potential disease-related variants allowed the discovery of additional somatic variants in GIST samples, apart from the known oncogenic driver mutation, both from sequencing of FF and FFPE material. False positive and false negative calls were present almost exclusively in the analysis of FFPE of low quality. On the whole this study showed that WES is feasible also on FFPE specimens and that it is possible to easily select FFPE samples of high quality that yield sequencing results comparable to the FF counterpart. WES on FFPE material may represent an important and innovative source for GIST research and for other solid tumors, amenable of possible application in clinical practice.